New Culprit Identified in Metabolic Syndrome
Source Newsroom: Washington University in St. Louis
Newswise — A new study suggests uric acid may play a role in causing metabolic syndrome, a cluster of risk factors that increases the risk of heart disease and type 2 diabetes.
Uric acid is a normal waste product removed from the body by the kidneys and intestines and released in urine and stool. Elevated levels of uric acid are known to cause gout, an accumulation of the acid in the joints. High levels also are associated with the markers of metabolic syndrome, which is characterized by obesity, high blood pressure, elevated blood sugar and high cholesterol. But it has been unclear whether uric acid itself is causing damage or is simply a byproduct of other processes that lead to dysfunctional metabolism.
Published Aug. 7 in Nature Communications, the new research at Washington University School of Medicine in St. Louis suggests excess uric acid in the blood is no innocent bystander. Rather, it appears to be a culprit in disrupting normal metabolism.
“Uric acid may play a direct, causative role in the development of metabolic syndrome,” said first author Brian J. DeBosch, MD, PhD, an instructor in pediatrics. “Our work showed that the gut is an important clearance mechanism for uric acid, opening the door to new potential therapies for preventing or treating type 2 diabetes and metabolic syndrome.”
Recent research by the paper’s senior author, Kelle H. Moley, MD, the James P. Crane Professor of Obstetrics and Gynecology, and her collaborators has shown that a protein called GLUT9 is an important transporter of uric acid.
DeBosch, a pediatric gastroenterologist who treats patients at St. Louis Children’s Hospital, studied mice to learn what happens when GLUT9 stops working in the gut, essentially blocking the body’s ability to remove uric acid from the intestine. In this study, the kidney’s ability to remove uric acid remained normal.
Eating regular chow, mice missing GLUT9 only in the gut quickly developed elevated uric acid in the blood and urine compared with control mice. And at only 6-8 weeks of age, they developed hallmarks of metabolic syndrome: high blood pressure, elevated cholesterol, high blood insulin and fatty liver deposits, among other symptoms.
The researchers also found that the drug allopurinol, which reduces uric acid production in the body and has long been used to treat gout, improved some, but not all, of the measures of metabolic health. Treatment with the drug lowered blood pressure and total cholesterol levels.
Exposure to uric acid is impossible to avoid because it is a normal byproduct of cell turnover in the body. But there is evidence that diet may contribute to uric acid levels. Many foods contain compounds called purines that break down into uric acid. And adding to growing concerns about fructose in the diet, evidence suggests that fructose metabolism in the liver also drives uric acid production.
“Switching so heavily to fructose in foods over the past 30 years has been devastating,” Moley said. “There’s a growing feeling that uric acid is a cause, not a consequence, of metabolic syndrome. And now we know fructose directly makes uric acid in the liver. With that in mind, we are doing further research to study what happens to these mice on a high-fructose diet.”
This work was supported by the Pediatric Scientist Development Program of the National Institutes of Health (NIH), grant 5K12HD000850-27, DDRCC grant P30DK52574, and R01HD040390-07; the German Ministry of Education and Research; and the State of Brandenburg. The Washington University Mouse Diabetes Model Phenotyping Core is supported by DRTC grant P60 DK020579. Mass spectrometry was performed in the Metabolomics Facility at Washington University (P30 DK020579).
DeBosch BJ, Kluth O, Fujiwara H, Schurmann A, Moley KH. Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. Nature Communications. Aug. 7, 2014.
Washington University School of Medicine’s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.